Antonio Giordano to Piperazines
This is a "connection" page, showing publications Antonio Giordano has written about Piperazines.
Connection Strength
1.330
-
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
Score: 0.609
-
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle. 2013 Sep 01; 12(17):2839-48.
Score: 0.394
-
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019 Jun; 54(6):2189-2199.
Score: 0.146
-
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. J Cell Physiol. 2019 06; 234(6):7708-7717.
Score: 0.143
-
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 10; 20(10):1360-1369.
Score: 0.038